Vertex nears Orkambi reimbursement agreement with Australia

Australia's Pharmaceutical Benefits Advisory Committee (PBAC) recommended in July that the government subsidize the price of Orkambi lumacaftor/ivacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX). The

Read the full 240 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE